<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190526043710N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-08-05</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of efficacy of anitibitic befor and after C/S to prevent post_cesarean infection</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of efficacy of prophylactic antibiotic prescribing before cesarean section and antibiotic administration after cord clamping on prevention of post-cesarean infection</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>180</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39985</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization method: Simple
Random unit: Individual
Randomization Tool: Random Number Tables
How to create a random sequence: A random number table using www.randomization.com
Hiding: Hiding in this study will be done by the central service and people who do not have any information about the research, Blinding description: Patients will be treated by prescription drug packs (which are quite similar in appearance).Patient and executor are not aware of the contents of packages. Information gathering, patient assessment and completion of the forms will be carried out by the executor and her assistant who are not aware of the contents of packages. The data analysis will also be done by the statistician who is not aware of packages contents and only is aware of the grouping (group 1 or 2). Therefore, the study is a triple blinded study and the patient's arrival stage to the study, data collection and analysis, the contents of the packs will not be determined.</study_design>
      <phase>3</phase>
      <hc_freetext>Comparison of efficacy of  antibiotic prescribing before and after cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 90 pregnant mothers eligible for inclusion in the study will be prescribed antibiotics (routinely: single dose Cefazolin 1 g in subjects weighing less than 80 kg - 2 g in subjects weighing 80 kg or more- 3 g in subjects With weight greater than 120 kg, and in the case of allergy to penicillin, combine therapy with Metronidazole 100 mg or 600 mg of Clindamycin with Gentamycin 1.5 mg / kg body weight) after clamping the umbilical cord and Distilled water one hour before making the cut (cesarean section). Intervention 2: Control group: 90 pregnant mothers eligible for inclusion in the study will be taken antibiotics (routinely: single dose Cefazolin 1 g in subjects weighing less than 80 kg - 2 g in subjects weighing 80 kg or more- 3 g in subjects With a weight greater than 120 kg, and in the case of allergy to penicillin, combine therapy with Metronidazole 100 mg or 600 mg of Clindamycin with Gentamycin 1.5 mg / kg body weight) One hour before making the cut (cesarean section) and distilled water immediately after cord clamping.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zeinab Shahbazzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 41, Alaei Sagharloo Alley, West 194 Ave, Tehranpars third Square, Tehranpars Town</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1653888344</zip>
        <telephone>+98 21 7773 4246</telephone>
        <email>shahbazzadeZ90@medsab.ac.ir</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mitra Eftekhar Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sabzevar Shahidan Mobini hospital, North Kashefi Ave</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9613873136</zip>
        <telephone>+98 51 4423 8100</telephone>
        <email>m_eftekhari1144@yahoo.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women who undergo C/S due to midwifery indications or other reasons
Providing informed consent</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having underlying dieases (DM, liver dieases, kidney dieases, suppressd immune sys)
The presence of chorioamnionitis criteria (loshia, tenderness, fever)
Fever (oral temperature above 38 degrees)
Rupture of memberans more than 24 hours
Immunosuppressive drugs use (corticosteroids and etc)
Use of antibiotics 24 hours before cesarean section</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 90 pregnant mothers eligible for inclusion in the study will be prescribed antibiotics (routinely: single dose Cefazolin 1 g in subjects weighing less than 80 kg - 2 g in subjects weighing 80 kg or more- 3 g in subjects With weight greater than 120 kg, and in the case of allergy to penicillin, combine therapy with Metronidazole 100 mg or 600 mg of Clindamycin with Gentamycin 1.5 mg / kg body weight) after clamping the umbilical cord and Distilled water one hour before making the cut (cesarean section).</i_keyword>
      <i_keyword>Control group: 90 pregnant mothers eligible for inclusion in the study will be taken antibiotics (routinely: single dose Cefazolin 1 g in subjects weighing less than 80 kg - 2 g in subjects weighing 80 kg or more- 3 g in subjects With a weight greater than 120 kg, and in the case of allergy to penicillin, combine therapy with Metronidazole 100 mg or 600 mg of Clindamycin with Gentamycin 1.5 mg / kg body weight) One hour before making the cut (cesarean section) and distilled water immediately after cord clamping.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incidence of post Cesarean infection. Timepoint: During the Hospitalization and 10 or 14 days after cesarean section. Method of measurement: Physical examination and judgment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-25</approval_date>
        <contact_name>Ethics committee of Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Sabzevar University of Medical Sciences, Tohidshahr Blvd Sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
